Dr Kevin Damman, MD, PhD, FHFA, studied medicine at the University of Groningen, The Netherlands and received his PhD in 2009 entitled “Cardiorenal Interaction in Heart Failure”. Dr Damman is a clinical cardiologist, head of the heart transplant and ventricular assist device program at the University Medical Center Groningen. His interests include advanced and acute heart failure. Current research interests are focused on improving treatment of acute heart failure patients, including SGLT2-inhibition in (acute) heart failure and the role of the kidney in the process of cardiorenal interaction. He is principle investigator of the EMPA-RESPONSE-AHF study on empagliflozin in acute heart failure and is part of the steering committee of the ADVOR trial investigating acetazolamide in acute heart failure. Dr Damman is associate editor of the European Journal of Heart Failure and is member of the working groups on Cardiorenal Dysfunction and Acute Heart Failure from the HFA.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease